Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Nai-Wen Mei has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to a distinct examiner, Ashlee Elizabeth Wertz. Consequently, Ashlee Elizabeth Wertz is the busiest examiner for this portfolio, managing 1 pending office action. This single matter represents the entire pending workload for the applicant at this time, creating a focused prosecution environment within the Biotechnology & Pharmaceuticals sector.
The prosecution is focused within 1 distinct art unit, which aligns with the technical classification of the filing. With only a distinct examiner and the pending office action, the applicant's experience is defined by a single point of contact within the USPTO. This allows for a targeted response strategy focused on the requirements of Ashlee Elizabeth Wertz and the specific standards of the 1 distinct art unit. Practitioners can dedicate their resources to this specific interaction without divergent feedback.
The presence of the pending office action suggests a streamlined interaction with the USPTO, where the outcome of the pending portfolio rests on the resolution of this matter. Consistency in communication with the examiner is essential for progress. Practitioners should prioritize the feedback from Ashlee Elizabeth Wertz, as her interpretation will determine the outcome for the 1 pending office action. The focused nature of this portfolio in the Biotechnology & Pharmaceuticals area allows for a dedicated strategy.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WERTZ, ASHLEE ELIZABETH | 1 | 49.1% | +40.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19001571 | THREE-DIMENSIONAL NETWORK AQUEOUS GEL AND MANUFACTURING METHOD THEREOF | WERTZ, ASHLEE ELIZABETH | — |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19001571 | THREE-DIMENSIONAL NETWORK AQUEOUS GEL AND MANUFACTURING METHOD THEREOF | WERTZ, ASHLEE ELIZABETH | 1612 | §103 | Non-Final OA | — | Pending | Dec 26, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNai-Wen Mei has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Ashlee Elizabeth Wertz has the most, with 1 of Nai-Wen Mei's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.